|
Biopharmaceuticals are the fastest growing category of therapeutics and are forecasted to be six of the top ten drugs by 2014. The current paradigm of delivery requires nearly all of these drugs to be administered by large volume, aqueous injection or infusion, often in a clinical setting. The patient experience is often unpleasant and difficult to manage resulting in reduced compliance and higher costs of administration.
Xeris aspires to change the paradigm for injection by developing ultra-low-volume, ready-to-use pharmaceuticals delivered through patient-friendly injection devices. Many of these devices would be self-administered in the comfort of the patient’s home. Inconvenient reconstitution of drugs in ampoules and vials followed by large volume, painful injections has been the standard for decades. Products developed leveraging Xeris’ non-aqueous formulation and delivery technologies will establish a new paradigm eliminating reconstitution, simplifying administration, and easing the pain of injections for millions of patients and caregivers.
|
